Home
About
Overview
Sharing Data
ORCID
Help
History (0)
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Vokes, Everett E.
One or more keywords matched the following items that are connected to
Vokes, Everett E.
Item Type
Name
Concept
Remission Induction
Academic Article
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Academic Article
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Academic Article
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Academic Article
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
Academic Article
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Academic Article
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Academic Article
Induction chemotherapy: to use or not to use? That is the question.
Academic Article
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
Academic Article
Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
Academic Article
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
Search Criteria
Remission Induction